Ivermectin is an antiparasitic drug originally used for treating infections in both humans and animals. Recent research shows that it may also target cancer metabolism, immune evasion, and mitochondrial function. In Protocol 2, it is used strategically on radiation days to amplify cancer cell sensitivity to oxidative stress.
⚠️ Disclaimer: While Ivermectin has shown promise in cancer research, it is a prescription medication.
We cannot recommend using paste formulations, even though they may contain the same active compound equivalent dosage of 1 gram per 150lbs of body weight.
Only a licensed medical professional can legally prescribe Ivermectin for human use.
🔍 Ivermectin – Protocol 2 Summary
✅ Best Timing:
- 6:30 AM during the Metabolic Ignition Phase on radiation days only
- Taken in the fasted state, with fat for enhanced absorption
- Avoid on non-radiation days to prevent adaptation and unnecessary exposure
💊 Recommended Dose:
- 50–62 mg (based on body weight)
- General guideline: ~1 mg per 3–4 lbs of body weight
- For example, 150–185 lb range = 50–62 mg
- Always verify human-grade, pharmaceutical sources
⏳ Active Duration in Body:
- Peak effect in 3–6 hours after dosing
- Half-life ~18 hours in humans
- Avoid daily use to maintain mitochondrial sensitivity
🔁 Redundancy With:
- Synergistic with Fenbendazole, Artemisinin, and radiation
- Partially overlaps with metabolic stress agents, but mechanism is distinct (targets import/export proteins, mitochondrial function)
- Not redundant with antioxidants, but should be avoided with antioxidant intake
📉 Pathways Inhibited or Affected:
- P-glycoprotein inhibition – blocks drug-resistance pumps used by cancer cells
- Wnt/β-catenin pathway suppression – prevents uncontrolled growth and survival
- Mitochondrial membrane disruption – weakens energy production in cancer cells
- Reduces stem-like cancer cell traits – which are often resistant to standard therapy
- May enhance ROS sensitivity during radiation or oxidative windows
🔒 Final Summary
Ivermectin is a mitochondrial disruptor and cellular gatekeeper inhibitor. In Protocol 2, it is used only on radiation days, at a dose of 50–62 mg, taken at 6:30 AM during the Metabolic Ignition Phase. It helps weaken cancer’s resistance to oxidative therapy by targeting drug-efflux pumps, stemness pathways, and mitochondrial membranes.
⚠️ Important: Only take human-prescribed Ivermectin from a licensed medical provider. paste or off-label use is not recommended.